EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Rhupus Syndrome With Multiple Drug Intolerances Managed by Reduced-dose Rituximab and Adjunctive Molecular Hydrogen Therapy: A Case Report

Han-Luen Tsai, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu

In Vivo · 2026

DOI: 10.21873/invivo.14221 ↗

Kurz gefasst

Fallbericht in der Zeitschrift In Vivo, 2026. Verfasst von Han-Luen Tsai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Rituximab, Hydrogen, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Rhupus syndrome, an overlap of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), is a rare condition characterized by heterogeneous clinical manifestations and difficult management. Conventional therapies, including glucocorticoids, disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressants, and biologics, are often limited by drug intolerance and steroid-related complications. Molecular hydrogen (H2) has emerged as a potential adjuvant therapy due to its antioxidant and immunomodulatory properties. This report aimed to evaluate the clinical efficacy of H2 as an adjunct to rituximab in a patient with refractory Rhupus and multiple drug intolerances. CASE REPORT: We report a 47-year-old male with a 27-year history of rheumatoid arthritis, who subsequently developed systemic lupus erythematosus, fulfilling criteria for Rhupus syndrome. His disease course was complicated by multiple drug intolerances, including adverse reactions to methotrexate, sulfasalazine, hydroxychloroquine, azathioprine, leflunomide, and rituximab at standard dosing. Despite reduced-dose rituximab and mycophenolic acid, disease activity persisted and lupus nephritis was confirmed. In October 2023, oral molecular hydrogen capsule therapy was initiated as adjuvant treatment, resulting in significant clinical improvement, which was paralleled by characteristic changes in T- and B-cell subsets, normalization of anti-dsDNA antibody, erythrocyte sedimentation rate (ESR), and complement levels, and successful discontinuation of prednisone. Hydrogen therapy was well tolerated without major adverse effects. The patient developed avascular necrosis from prior corticosteroid use but recovered well after hip arthroplasty in January 2025. Disease control was sustained with mycophenolic acid and continued hydrogen therapy. CONCLUSION: This case suggests molecular hydrogen therapy as a potential adjuvant for refractory Rhupus with multiple drug intolerances, showing immune modulation, reduced inflammation, steroid withdrawal, and sustained control with low-dose rituximab. Further studies are needed to confirm its efficacy and standardize its use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabHydrogenLupus Erythematosus, SystemicArthritis, RheumatoidHumansMaleMiddle AgedAntirheumatic AgentsTreatment Outcome

Stichwörter der Autor:innen

Case reportRhupus syndromehydrogen therapyrheumatoid arthritissystemic lupus erythematosus

Substanzen

RituximabHydrogenAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, R.O.C.
  • Department of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung, Taiwan, R.O.C.
  • Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
  • The Finsen Laboratory, Rigshospitalet/National University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • School of Pharmacy, National Defense Medical University, Taipei, Taiwan, R.O.C.
  • Graduate Institute of Life Sciences, National Defense Medical University, Taipei, Taiwan, R.O.C.

Zitieren

APA

Tsai, H. L., Lu, J. W., Ho, Y. J., Lui, S. W., Hsieh, T. Y., Wang, K. Y., & Liu, F. C. (2026). Rhupus Syndrome With Multiple Drug Intolerances Managed by Reduced-dose Rituximab and Adjunctive Molecular Hydrogen Therapy: A Case Report. In Vivo. https://doi.org/10.21873/invivo.14221

Vancouver

Tsai HL, Lu JW, Ho YJ, Lui SW, Hsieh TY, Wang KY, et al. Rhupus Syndrome With Multiple Drug Intolerances Managed by Reduced-dose Rituximab and Adjunctive Molecular Hydrogen Therapy: A Case Report. In Vivo. 2026. doi:10.21873/invivo.14221

BibTeX
@article{Tsai2026,
  author = {Tsai, Han-Luen and Lu, Jeng-Wei and Ho, Yi-Jung and Lui, Shan-Wen and Hsieh, Ting-Yu and Wang, Kuang-Yih and Liu, Feng-Cheng},
  title = {Rhupus Syndrome With Multiple Drug Intolerances Managed by Reduced-dose Rituximab and Adjunctive Molecular Hydrogen Therapy: A Case Report},
  journal = {In Vivo},
  year = {2026},
  doi = {10.21873/invivo.14221}
}
Kostenlos starten →